{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-027072","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.953186+00:00","generated_at":"2026-05-16T13:40:33.163882+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MAIA touts $50B immunotherapy market; ateganosine gets Fast Track for NSCLC, Phase 3 starting","bullets":["FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.","Initiating Phase 3 THIO-104 trial for advanced NSCLC without actionable mutations and CPI-refractory.","FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma, and small cell lung cancer.","NSCLC market valued at $34.1B, projected to nearly double to $68.8B by 2033.","Keytruda generated $29.5B revenue in 2024, with ~30% from NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-027072","json":"https://secwatch.observer/filing/0001493152-25-027072.json","markdown":"https://secwatch.observer/filing/0001493152-25-027072.md","text":"https://secwatch.observer/filing/0001493152-25-027072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225027072/0001493152-25-027072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225027072/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:40:33.163882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}